Mucormycosis after allogeneic haematopoietic stem cell transplantation: A French Multicentre Cohort Study (2003-2008)

Clinical Microbiology and Infection

Volumn 18, Issue 10, 2012, Pages

  Xhaard, A ^a,b   Lanternier, F ^c,d   Porcher, R ^a,b   Dannaoui, E ^d,e   Bergeron, A ^a,b   Clement, L ^f   Lacroix, C ^a,b   Herbrecht, R ^g   Legrand, F ^h   Mohty, M ⁱ   Michallet, M ^j   Cordonnier, C ^k   Malak, S ^l   Guyotat, D ^m   Couderc, Lj ⁿ   Socie G ^a,b   Milpied, N ^o   Lortholary, O ^c,d   Ribaud, P ^a,b  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d INSTITUT PASTEUR   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f UNIVERSITY HOSPITAL OF NANCY   (France)

^g UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^h UNIVERSITY HOSPITAL OF BESANÇON   (France)

ⁱ NANTES UNIVERSITY HOSPITAL   (France)

^j HOSPICES CIVILS DE LYON   (France)

^k HENRI MONDOR HOSPITAL   (France)

^l ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^m UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

ⁿ FOCH HOSPITAL   (France)

^o BORDEAUX UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Allogeneic haematopoietic stem cell transplantation; Mucormycosis

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; ITRACONAZOLE; POSACONAZOLE; STEROID; VORICONAZOLE;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CAUSE OF DEATH; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPIDEMIOLOGICAL DATA; FEMALE; FRANCE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; MALE; MORTALITY; MUCORMYCOSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; STEROID THERAPY; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC MYCOSIS; TREATMENT FAILURE;

EID: 84866162897     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2012.03908.x     Document Type: Article

References (19)

1. Ambrosioni J, Bouchuiguir-Wafa K, Garbino J. Emerging invasive zygomycosis in a tertiary care center: epidemiology and associated risk factors. Int J Infect Dis 2010; 14 (suppl 3): e100-e103.
2. Saegeman V, Maertens J, Meersseman W, Spriet I, Verbeken E, Lagrou K. Increasing incidence of mucormycosis in University Hospital, Belgium. Emerg Infect Dis 2010; 16: 1456-1458.
3. Marr KA, Carter RA, Crippa F, Wald A, Corey L Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-917.
4. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191: 1350-1360.
5. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634-653.
6. Bitar D, Van Cauteren D, Lanternier F et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis 2009; 15: 1395-1401.
7. Neofytos D, Horn D, Anaissie E et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009; 48: 265-273.
8. Lanternier F, Dannaoui E, Morizot G. A global analysis of mucormycosis in France: the RetroZygo Study. Clin Infec Dis 2012; 54 (suppl 1): S35-S43.
9. Segal BH, Herbrecht R, Stevens DA et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008; 47: 674-683.
10. Sullivan KM. Graft-vs-host disease. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic cell transplantation, 2nd edn. Malden, MA: Blackwell Science, 1999; 515-536.
11. Kontoyiannis DP, Marr KA, Park BJ et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50: 1091-1100.
12. Park BJ, Pappas PG, Wannemuehler KA et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis 2011; 17: 1855-1864.
13. Maertens J, Demuynck H, Verbeken EK et al. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant 1999; 24: 307-312.
14. Pagano L, Caira M, Candoni A et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91: 1068-1075.
15. Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008; 47: 1041-1050.
16. Trifilio S, Singhal S, Williams S et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007; 40: 451-456.
17. Skiada A, Pagano L, Groll A et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group On Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011; 17: 1859-1867.
18. Pagano L, Offidani M, Fianchi L et al. Mucormycosis in hematologic patients. Haematologica 2004; 89: 207-214.
19. Singh N, Aguado JM, Bonatti H et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis 2009; 200: 1002-11.